Loading…
One of Japan's largest generic pharmaceutical manufacturers, supplying off-patent drugs nationwide.
One of Japan's largest generic pharmaceutical manufacturers, supplying off-patent drugs nationwide.
Sold to hospitals and pharmacies through wholesalers, with prices set on the government's reimbursement list and cut in regular revisions, so the volume of generic substitution matters more than price. Profit depends on running plants efficiently as unit prices fall.
In one line: Japan's Viatris / Teva.
Moat: none (scale, regulatory licence). Generic drug maker competing on cost and government-mandated price cuts, with little product differentiation.
Headquarters: Osaka, Japan · Founded: 1929 · Employees: 3,630
Size SAWAI (4887.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $1.03B, the 724th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥1,632 on 6 Nov 2026.
Performance Over six months the shares fell 22.4%, against -11.0% for the median peer and +1.8% for the Japan market (cap-weighted) — 5th lowest of 20 in its peer set.
Growth Revenue grew 11.1% over the last twelve months (peer median +5.8%); the operating margin is 9.1% (peer median 7.0%).
Valuation It trades at 10.9× forward earnings against a peer median of 21.5× (3rd cheapest of 13).
Capital Return on invested capital runs 1.0 points below its cost of capital (5.0% WACC).
Next results Next results expected around 13 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥216B | ¥202B | ¥189B | ¥177B | ¥164B |
| Revenue growth | — | +7% | +7% | +8% | — |
| Gross profit | ¥61.9B | ¥58.8B | ¥56.4B | ¥54.3B | ¥50.3B |
| EBITDA | ¥37.1B | ¥36.4B | ¥35.5B | ¥36.9B | ¥33.2B |
| Net income | ¥8.54B | ¥10.4B | ¥12.0B | ¥13.7B | ¥12.7B |
| Free cash flow | -¥3.74B | -¥5.98B | ¥7.28B | ¥5.23B | -¥7.70B |
| Capital expenditure | ¥31.6B | ¥24.5B | ¥27.5B | ¥24.6B | ¥27.1B |
| Total debt | ¥149B | ¥109B | ¥95.1B | ¥87.1B | ¥77.1B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| SAWAI 4887.T | $1.03B | -22% | +11% | 9% | 10.9× | n/a |
| Towa Pharmaceutical 4553.T | $1.03B | -16% | +7% | 9% | 7.0× | 1.5% |
| Viatris VTRS | $22.9B | +17% | +5% | 10% | 7.5× | 12.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4887.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.1% | -3.4% | 8th highest of 21 |
| 6-month return | -22.4% | -11.0% | 5th lowest of 20 |
| Distance from 52-week high | -33.3% | -30.2% | 10th lowest of 21 |
| Revenue growth (TTM) | +11.1% | +5.8% | 7th highest of 19 |
| Operating margin | 9.1% | 7.0% | 8th highest of 19 |
| Forward P/E | 10.9× | 21.5× | 3rd cheapest of 13 |
| ROIC minus cost of capital | -1.0 pp | -1.1 pp | 9th highest of 17 |
| EV / EBITDA | 7.5× | 13.2× | 2nd cheapest of 8 |
| Net debt / EBITDA | 3.1× | 0.4× | 3rd most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SAWAI 4887.T | Japan | $1.03B | -22% | +11% | 9% | 10.9× | n/a | n/a |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.03B | n/a | n/a | n/a | n/a | n/a | n/a |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -16% | +7% | 9% | 7.0× | 1.5% | +12.1% |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $1.03B | -11% | -43% | -42% | n/a | 11.9% | -13.7% |
| Oscotec 039200.KS | South Korea | $1.02B | -30% | +233% | 62% | 56.8× | -9.5% | +18.1% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -13% | +31% | -7% | 4.8× | -6.4% | -7.7% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $1.05B | -6% | +8% | 7% | 21.0× | 3.4% | +1.8% |
| Harrow HROW | United States | $1.01B | -30% | +21% | 2% | 21.9× | 51.8% | +41.0% |
| KPC Pharmaceuticals 600422.SS | China | $1.00B | -7% | -41% | -10% | n/a | n/a | n/a |
| Renhe Pharmacy 000650.SZ | China | $1.06B | -10% | -7% | 14% | 17.7× | -9.4% | -7.0% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $1.06B | -18% | -27% | -19% | 23.8× | n/a | n/a |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $999M | -15% | -16% | 13% | n/a | 8.8% | -6.9% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $1.07B | -47% | -55% | -457% | n/a | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.07B | +27% | +5% | 24% | 12.4× | -5.7% | +12.7% |
| Savara SVRA | United States | $992M | -8% | n/a | n/a | n/a | n/a | n/a |
| Viyash Scientific VIYASH.NS | India | $1.07B | +3% | +96% | 13% | 30.3× | 38.6% | +20.4% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.07B | -38% | +117% | -89% | n/a | n/a | n/a |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $1.07B | -15% | +8% | 7% | n/a | 34.1% | -6.0% |
| SSY 2005.HK | Hong Kong | $990M | +10% | -4% | 12% | 13.0× | 2.1% | -0.5% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.08B | -2% | +27% | 4% | 22.7× | 5.0% | +3.5% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $983M | -7% | +2% | 24% | 24.4× | 10.2% | +13.4% |